Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Pharmaceutical company Eli Lilly and Company, currently best known for its diabetes and obesity GLP-1 therapies, contributed to performance as commercial execution and pipeline data reinforced investor confidence in the company's long-term leadership. All three major...
— Neal Kaufman
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Eli Lilly and Company
We also continued to add to Eli Lilly and Company in the third quarter. Lilly is best...
Eli Lilly and Company ($LLY) is a global pharmaceutical leader specializing in treatments for diabetes, obesity, oncology, and immunology, representing the Fund's largest portfolio holding at 14.3% of net assets. The manager maintains...
Eli Lilly is a premier multinational pharmaceutical company engaged in the research, development, and commercialization of therapeutics, currently dominating the global market for diabetes and obesity treatments. The manager is...
More institutional theses from Baron Health Care Fund
Eli Lilly and Company ($LLY) is a global pharmaceutical leader specializing in treatments for diabetes, obesity, oncology, and immunology, representing the Fund's largest portfolio holding at 14.3% of net assets. The manager maintains...
Thermo Fisher Scientific Inc. ($TMO) is the world's premier provider of life sciences tools, laboratory supplies, analytical instruments, and clinical trial services, representing 5.9% of fund assets. The investment manager...
Xenon Pharmaceuticals Inc. ($XENE) is a clinical-stage biopharmaceutical developer focused on novel ion channel therapies for neurological disorders. The manager adopted...